Patents by Inventor Robert D'Amato
Robert D'Amato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10286032Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.Type: GrantFiled: June 22, 2015Date of Patent: May 14, 2019Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Patent number: 9789199Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: GrantFiled: September 12, 2016Date of Patent: October 17, 2017Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Patent number: 9782489Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: GrantFiled: August 26, 2016Date of Patent: October 10, 2017Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Patent number: 9597371Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: GrantFiled: October 28, 2013Date of Patent: March 21, 2017Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Publication number: 20160375144Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Publication number: 20160361428Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: ApplicationFiled: August 26, 2016Publication date: December 15, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Patent number: 9446140Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: GrantFiled: June 24, 2014Date of Patent: September 20, 2016Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20160136292Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: January 25, 2016Publication date: May 19, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra BENNY-RATSABY, Robert D'AMATO, Judah FOLKMAN
-
Patent number: 9272050Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: GrantFiled: September 24, 2014Date of Patent: March 1, 2016Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Publication number: 20150359842Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.Type: ApplicationFiled: June 22, 2015Publication date: December 17, 2015Inventors: Avner Adini, Robert D'Amato
-
Patent number: 9090707Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.Type: GrantFiled: January 27, 2011Date of Patent: July 28, 2015Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Publication number: 20150104406Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: ApplicationFiled: September 24, 2014Publication date: April 16, 2015Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Patent number: 8865151Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.Type: GrantFiled: December 28, 2009Date of Patent: October 21, 2014Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
-
Publication number: 20140301969Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: ApplicationFiled: June 24, 2014Publication date: October 9, 2014Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Patent number: 8790634Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.Type: GrantFiled: December 28, 2009Date of Patent: July 29, 2014Assignee: Children's Medical Center CorporationInventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
-
Publication number: 20140194358Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: ApplicationFiled: October 28, 2013Publication date: July 10, 2014Applicant: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Patent number: 8618055Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: GrantFiled: January 27, 2011Date of Patent: December 31, 2013Assignee: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Publication number: 20130045922Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.Type: ApplicationFiled: January 27, 2011Publication date: February 21, 2013Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Avner Adini, Robert D'Amato
-
Publication number: 20120142734Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.Type: ApplicationFiled: February 14, 2012Publication date: June 7, 2012Inventor: Robert D'Amato
-
Publication number: 20120114668Abstract: Described herein are compositions and uses thereof to inhibit or enhance the activity of fibromodulin (FMOD). Such compositions are useful in methods for treatment of age-related macular degeneration involving choroid neovascularization in a subject comprising administering a therapeutically effective amount of a fibromodulin activity inhibitor to the subject.Type: ApplicationFiled: November 7, 2011Publication date: May 10, 2012Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Irit Adini, Robert D'Amato